12 results about "Lipid binding" patented technology

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

[Problem] To provide, inter alia, an information processing system with which it is possible to accurately estimate binding force to lipid [Solution] According to one aspect of the present invention, provided is an information processing system comprising a processor configured to execute the next steps by reading a program. In an acquisition step, an amino acid sequence for which an inference is to be carried out is acquired. In an inference step, the binding force, to lipid, of a protein having the amino acid sequence for which an inference is to be carried out is inferred on the basis of the amino acid sequence for which an inference is to be carried out, and reference information. The reference information includes a correlation between the amino acid sequence and the binding force, the correlation being constructed on the basis of actually measured values of the binding force.

This invention relates to the fields of environmental and bioanalytical technology, and particularly to a method for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. The technical solution includes a framework process for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. This invention establishes a dual-solvent secondary extraction system composed of n-hexane and methyl tert-butyl ether, achieving differentiated adaptation to different tissue matrices. By combining the advantages of non-polar and moderately polar solvents, it can simultaneously handle the relatively highly polar bisphenol S and the relatively non-polar bisphenol AF in a single extraction process. Furthermore, this method sets key physical parameters during the extraction process according to the histological characteristics of each organ. For heart and lung tissues, specific ultrasonic power is used to ensure thorough cell disruption; while for liver and spleen with high lipid content, different power and time are used to ensure the full release of lipid-bound target substances.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

Methods of using a lipid binding protein molecule to treat a subject having one or more conditions or at risk of one or more conditions. The method generally includes measuring ApoA-I levels and / or HDL cholesterol levels in the subject, and administering one or more doses of the lipid binding protein molecule to the subject if the measured ApoA-I levels are below a target ApoA-I level or target ApoA-I range, and / or the measured HDL levels are below a target HDL level.

The invention discloses application of morusin O in preparation of a TEAD protein palmitoylation inhibitor, and relates to the technical field of molecular biology. The invention also provides a TEAD palmitoylation inhibitor and a method for screening the TEAD palmitoylation inhibitor in vitro. It is found for the first time that the compound can be directly combined with a lipid binding pocket of TEAD1 protein to interfere the post-translational palmitoylation modification level of the TEAD1 protein, so that the conformational stability and transcriptional activity of TEAD1 are reduced, and the application value is wide.

A lipid-binding protein comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the glycine residue at position 12 from the N-terminus of the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid residue selected from the group consisting of cysteine, valine, leucine, isoleucine, alanine, and methionine, and wherein the lipid-binding protein has a higher binding affinity for PI(3,5)P₂ than a protein consisting of the amino acid sequence of SEQ ID NO: 1.

This disclosure provides therapeutic nanodiscs comprising a lipid-binding polypeptide, a lipid bilayer, and a therapeutic agent, wherein the therapeutic agent may be used to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries. The lipid bilayer may be 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), and the therapeutic agent may be a nucleic acid polymer. Furthermore, methods for administering therapeutic nanodiscs to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries, as well as the use of such therapeutic nanodiscs, are provided.

The present invention provides compounds used for the treatment of acute conditions including sepsis, sepsis-associated AKI, ischemia / reperfusion AKI, and CSA AKI, as well as CRS, such as CRS associated with immunotherapy and CRS secondary to infections like COVID-19. [Solution] A lipid-binding protein-based complex is provided for use in a method of treating an acute condition, the method comprising the step of administering a high dose of the lipid-binding protein-based complex to a subject in need thereof, the acute condition may include acute inflammation.